WO2002102781A1 - Procedimiento para la preparación de derivados de 1,5-diaril-3-trifluorometil-delta2-pirazolinas racémicas y enantioméricamente puras - Google Patents
Procedimiento para la preparación de derivados de 1,5-diaril-3-trifluorometil-delta2-pirazolinas racémicas y enantioméricamente puras Download PDFInfo
- Publication number
- WO2002102781A1 WO2002102781A1 PCT/ES2002/000274 ES0200274W WO02102781A1 WO 2002102781 A1 WO2002102781 A1 WO 2002102781A1 ES 0200274 W ES0200274 W ES 0200274W WO 02102781 A1 WO02102781 A1 WO 02102781A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- substituents
- group
- methyl
- trifluoromethyl
- chlorine
- Prior art date
Links
- 0 *C(CC1c2ccc(*I)cc2*)=**1c1ccc(*)cc1* Chemical compound *C(CC1c2ccc(*I)cc2*)=**1c1ccc(*)cc1* 0.000 description 4
- KWGRBVOPPLSCSI-PSASIEDQSA-N C[C@H]([C@H](c1ccccc1)O)NC Chemical compound C[C@H]([C@H](c1ccccc1)O)NC KWGRBVOPPLSCSI-PSASIEDQSA-N 0.000 description 2
- WQWLQBRQSNEUPY-AWEZNQCLSA-N OS(c(cc1)ccc1N([C@@H](C1)c(ccc(F)c2)c2F)N=C1C(F)(F)F)(=O)=O Chemical compound OS(c(cc1)ccc1N([C@@H](C1)c(ccc(F)c2)c2F)N=C1C(F)(F)F)(=O)=O WQWLQBRQSNEUPY-AWEZNQCLSA-N 0.000 description 2
- DYUQAZSOFZSPHD-SECBINFHSA-N CC[C@H](c1ccccc1)O Chemical compound CC[C@H](c1ccccc1)O DYUQAZSOFZSPHD-SECBINFHSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/06—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
Definitions
- the present invention relates to a new, commercially useful process for the preparation of compounds of general formula 1, which includes the racemic mixture ( ⁇ ) -1, and the enantiomerically pure compounds (-) - 1 and (+) - 1 .
- the mentioned patent describes the preparation of ( ⁇ ) -1 by reaction of (£) -1, 1, 1- trifluoro-4-aryl-3-buten-2-one with 4- (aminosulfonyl) phenylhydrazine or 4- (methylsulfonyl) phenylhydrazine, or by reaction of 4- (aryl) phenylhydrazine with (£) -1, 1, 1- trifluoro-4- (4-aminosulfonylphenyl) -3-buten-2-one or (£) -1, 1, 1-trifluoro-4- (4- methylsulfonylphenyl) -3-buten-2-one.
- This method suffers from the drawback of using successive recrystallizations, both in the sodium sulfonate formation process (between 3 and 7 recrystallizations) and in the formation and separation process of the mixture of diastereoisomeric salts (between 4 and 7 recrystallizations), which which entails a considerable decrease in performance.
- the object of the present invention is to provide a commercially useful process for the preparation of compounds of general formula 1, which includes the racemic mixture ( ⁇ ) -1 and the enantiomerically pure compounds (-) - 1 and (+) - 1, in which
- Ri YR 3 represent a hydrogen, chlorine, fluorine atom, a methyl, trifluoromethyl or methoxy group
- R 2 represents a hydrogen, chlorine, fluorine atom, a methyl, trifluoromethyl, methoxy, trifluoromethoxy, methylsulfonyl or aminosulfonyl group,
- R 4 represents a hydrogen, chlorine, fluorine atom, a methyl, trifluoromethyl, methoxy, trifluoromethoxy, methylsulfonyl or aminosulfonyl group, with the proviso that one of the R 2 or R 4 substituents is a methylsuiphonyl or aminosulfonyl group;
- the present invention provides a cheaper method of obtaining the racemic mixture ( ⁇ ) -1 than that previously described in the patent.
- racemic compound contains an amino group in its structure, it is possible to form diastereoisomeric salts with an optically active acid and if the racemic compound contains in its structure an acid group, it is possible to form diastereoisomeric salts with an optically active base. Since compound 1 lacks acidic or basic groups strong enough to form diastereoisomeric salts, in the present invention a procedure is developed which is outlined below (Scheme 1) to obtain the racemic mixture ( ⁇ ) -1 and the compounds enantiomerically pure (-) - 1 and (+) - 1.
- Compound (-) - 8 is synthesized according to the present invention by the method described below with preferred conditions indicated in the scheme.
- the resolution of the racemic mixture (+) - 6 in its two enantiomers is carried out, by forming a mixture of diastereoisomeric salts, using as a resolution agent (+) - ephedrine.
- Ephedrine is an excellent resolution agent, since both enantiomers can be used in the resolution, are available in high enantiomeric purity, are commercially accessible, and are readily recoverable and crystallizable.
- Compound (+) - 8 is prepared by the same synthetic route as in the previous case, changing only the enantiomer of ephedrine in the resolution process (step 3).
- the synthesis of the racemic compound ( ⁇ ) -8 is carried out in the same way, eliminating the steps related to resolution, that is, directly by reaction of the acid chloride with ammonia or ammonium carbonate.
- the first step is the preparation of pyrazoline ( ⁇ ) -5 from (£) -1,1, 1-trifluoro-4- (2,4-difluorophenyl) -3-buten-2-one and phenylhydrazine, in a suitable solvent such as, for example, alcohols such as methanol, ethanol or isopropanol, or in the absence of solvent.
- a suitable solvent such as, for example, alcohols such as methanol, ethanol or isopropanol, or in the absence of solvent.
- the reaction is carried out in an acidic medium, which can be organic, such as acetic acid or p-toluenesulfonic acid, or inorganic, such as, for example, hydrochloric acid, or a mixture of both, or in a basic medium such as eg piperidine, piperazine, sodium hydroxide, potassium hydroxide, sodium methoxide or sodium ethoxide, or a mixture thereof.
- the acidic or basic medium itself can also act as a solvent.
- the most suitable temperatures range between room temperature and 150 ° C, and the reaction times are between 2 and 48 hours.
- the purification of pyrazoline ( ⁇ ) -5 is carried out by crystallization.
- a sulfonation is carried out on the pyrazoline ( ⁇ ) -5 with chlorosulfonic acid without solvent or using a chlorinated solvent such as dichloromethane at temperatures ranging between 0 ° C and the boiling temperature of the solvent, obtaining the corresponding acid sulfonic after aqueous treatment.
- a chlorinated solvent such as dichloromethane
- sodium hydroxide sodium sulfonate ( ⁇ ) -6 precipitates.
- the racemic mixture ( ⁇ ) -6 in its two enantiomers is resolved by forming a mixture of two diastereoisomeric salts and subsequently separating one of them by precipitation in the same reaction medium.
- the procedure object of the present invention does not suffer from the drawbacks discussed above in the resolution of a similar product carried out by Mukai et al. [Dog. J. Chem. 1979 57, 360-366], and the separation of the two diastereoisomeric salts is carried out in the reaction medium itself in the process of formation of the mixture of diastereoisomeric salts, that is, only a single crystallization is necessary .
- the agent resolution used is (+) - ephedrine, which by reaction of the racemic mixture ( ⁇ ) -6 with (+) - ephedrine hydrochloride in a chlorinated solvent such as chloroform and at temperatures ranging from room temperature to reflux temperature, the mixture of diastereoisomeric salts is prepared, and in the cooling process exclusively the (-) - 7 enantiomer precipitates as (+) - ephedrine salt, with an enantiomeric excess greater than 98%.
- the diatereoisomeric salt of (+) - 7 and (+) - ephedrine can be obtained, by evaporation of the solvent and subsequent recrystallization from an alcohol such as isopropyl alcohol, or mixtures of an alcohol and water.
- step 3 of the scheme by carrying out the same process as in step 3 of the scheme, but using (-) - ephedrine hydrochloride, the diastereoisomeric salt formed by (+) - 7 and (-) - ephedrine and the liquids is obtained by precipitation Filtration can obtain the diatereoisomeric salt of (-) - 7 and (-) - ephedrine, by evaporation of the solvent and subsequent recrystallization from an alcohol such as isopropyl alcohol, or mixtures of an alcohol and water.
- an alcohol such as isopropyl alcohol, or mixtures of an alcohol and water.
- the sodium sulfonate (-) - 6 is enantiomerically liberated by basic hydrolysis of the salt (-) - 7 - (+) - ephedrine, with aqueous sodium hydroxide and using an alcohol such as isopropanol as a solvent.
- Ephedrine can be easily recovered from filter liquids, removing the solvent and acidifying the residue dissolved in ethanol with ethanolic hydrochloric acid.
- Obtaining the (+) - 6 enantiomer is carried out in the same way, from the salt (+) - 7 - (+) - ephedrine or (+) - 7 - (-) - ephedrine.
- the (-) - 8 stereoisomer is prepared with an enantiomeric excess greater than 99%, by reaction of the optically active sodium sulfonate (-) - 6 with thionyl chloride in the absence of solvent or in a suitable solvent such as toluene, at temperatures comprised between the room temperature and the reflux temperature, and subsequent formation of the suifonamide, adding ammonia or ammonium carbonate in the same reaction medium.
- the enantiomer (+) - 8 is obtained from (+) - 6.
- the racemic compound ( ⁇ ) -8 is obtained.
- Scheme 3 outlines another specific example of obtaining the compounds object of the present invention: obtaining (-) - 13.
- Compound (-) - 13 is synthesized, according to the present invention, by the method described below with preferred conditions indicated in the scheme.
- the resolution of the racemic mixture ( ⁇ ) -11 in its two enantiomers is carried out, by forming a mixture of diastereoisomeric salts, using as a resolution agent (+) - ephedrine to obtain the enantiomer (-) - 13 .
- Compound (+) - 13 is prepared by the same synthetic route as in the previous case, changing only the enantiomer of ephedrine in the resolution process (step 3).
- the synthesis of the racemic compound ( ⁇ ) -13 is carried out in the same way, suppressing the formation step of the ephedrine salt and its subsequent hydrolysis.
- the first step is the preparation of pyrazoline ( ⁇ ) -10 from (E) -1, 1, 1-trifluoro-5-phenyl-3-buten-2-one and 2,4-difluorophenylhydrazine hydrochloride, in a suitable solvent such as, for example, alcohols such as ethanol or in the absence of solvent.
- a suitable solvent such as, for example, alcohols such as ethanol or in the absence of solvent.
- the reaction takes place in an acidic medium, for example with acetic acid or p-toluenesulfonic acid.
- the most suitable temperatures range from room temperature to 110 ° C, and the reaction times are between 2 and 24 hours.
- the purification of pyrazoline ( ⁇ ) -10 is carried out by crystallization.
- a sulfonation is carried out on the pyrazoline ( ⁇ ) -10 with chlorosulfonic acid without solvent or using a chlorinated solvent such as dichloromethane at temperatures ranging between 0 ° C and the boiling temperature of the solvent, obtaining the corresponding acid sulfonic after aqueous treatment.
- a chlorinated solvent such as dichloromethane
- sodium hydroxide sodium sulfonate ( ⁇ ) -11 precipitates.
- the resolution of the racemic mixture is carried out ( ⁇ ) -11 in. its two enantiomers by formation of a mixture of two diastereoisomeric salts and subsequent separation of one of them by precipitation in the same reaction medium, with only a single crystallization being necessary.
- the sodium sulfonate (-) - 11 is enantiomerically liberated by basic hydrolysis of the salt (-) - 12 (+) - ephedrine, with aqueous sodium hydroxide and using water as solvent.
- Ephedrine as mentioned above, can be easily recovered from filter liquids by acidifying the residue dissolved in ethanol with ethanolic hydrochloric acid. Obtaining the (+) - 11 enantiomer is carried out in the same way, from the salt (+) - 12 - (+) - ephedrine or (+) - 12 - (-) - ephedrine.
- the (-) - 13 stereoisomer is prepared by reacting the optically active sodium sulfonate (-) - 11 with thionyl chloride in the absence of solvent or in a suitable solvent such as toluene, at temperatures between room temperature and reflux temperature, subsequent formation of sodium sulphinate by reaction of the acid chloride with sodium sulphite in a basic medium, and finally by reaction of the sodium sulphinate obtained with methyl iodide or methyl sulfate in a alcoholic or aqueous medium.
- the enantiomer (+) - 13 is obtained from (+) - 11.
- the racemic compound ( ⁇ ) -13 is obtained.
- the resolution procedure object of the present invention can be used for racemic mixtures (those in which the two enantiomers are in a 1: 1 ratio) or for non-racemic mixtures, in which one of the enantiomers is the majority, obtained by any method physical or chemical.
- the process of obtaining some of the compounds referred to in the present invention is shown below by way of example. These examples are shown by way of illustration only and should not in any way limit the scope of the present invention.
- aqueous phase is concentrated to two thirds of the initial volume and a 1M aqueous solution of sodium hydroxide (12.27 mL, 12.27 mmol) is added under stirring.
- a white solid corresponding to sodium sulfonate ( ⁇ ) -6 precipitates, which is filtered, washed with more water and dried (3.93 g, 75% yield): mp 292-295 ° C;
- (+) - ephedrine (-) - 4- [5- (2,4-difluorophenyl) -4,5-dihydro-3- (trifluoromethyl) -1 H-pyrazol-1-yl] -benzenesulfonate, ( -) - 7 - (+) - ephedrine.
- a sample (72 g) mixture of sodium (-) - 6 sulfonate (48.3 g, 112.8 mmol) and NaCI (23.7 g) on toluene (250 mL) is introduced into a 1 L flask.
- the suspension is heated to 60 ° C, thionyl chloride (18 mL, 247.5 mmol) is added, heated to reflux and kept at this temperature for at least 2 hours.
- excess thionyl chloride is removed by azeotropic distillation of the same with toluene (190 mL; 76 ° C at 60 mmHg). More toluene (190 mL) is added and it is distilled again under the same conditions.
- the previous sample is diluted with toluene (190 mL), the mixture is cooled to 70 ° C, ammonium carbonate in solid form (22.6 g, 235 mmol) is introduced, it is heated to 90 ° C and it is Stir at this temperature for 2 h. After the reaction (if necessary, add more ammonium carbonate), add water (300 mL) and keep 30 min at 90 ° C. The mixture is cooled to room temperature, an aqueous solution of
- the organic phase is dried with MgS ⁇ 4, filtered and the solvent is evaporated under reduced pressure.
- the crude obtained (3.6 g) is introduced into a 25 mL flask coupled to a refrigerant and water (13.4 mL) is added to it.
- the suspension is heated to 70 ° C and an aqueous solution of 10M sodium hydroxide (1.7 mL, 17.04 mmol) is added slowly and with stirring.
- the mixture is heated under reflux and kept at this temperature for 10 minutes.
- compound (-) - 11 230 mg, 0.54 mmol
- toluene 1.1 mL
- thionyl chloride 88 ⁇ L, 1.18 mmol
- excess thionyl chloride is removed by azeotropic distillation thereof with toluene (76 ° C at 60 mmHg). More toluene (1 mL) is added and it is distilled again under the same conditions.
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Abstract
Description
Claims
Priority Applications (20)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IL15936702A IL159367A0 (en) | 2001-06-18 | 2002-06-06 | Method of preparing derivatives of 1,5-diaryl-3-trifluoromethyl-delta 2 pyrazolines that are racemic and enantiomerically pure |
DE60208551T DE60208551T2 (de) | 2001-06-18 | 2002-06-06 | Verfahren zur herstellung von racemischen und enantiomerenreinen derivaten von 1,5-diaryl-3-trifluormethyl-delta2-pyrazolinen |
US10/312,194 US6846935B2 (en) | 2001-06-18 | 2002-06-06 | Procedure for the preparation of racemic and enantionmerically pure derivatives of 1,5-diaryl-3-trifluoromethyl-Δ2-pyrazolines |
EEP200400016A EE200400016A (et) | 2001-06-18 | 2002-06-06 | Protsess 1,5-diarüül-3-trifluorometüül-delta²-pürasoliinide ratseemiliste ja enantiomeerselt puhaste derivaatide valmistamiseks |
JP2003505323A JP2005502604A (ja) | 2001-06-18 | 2002-06-06 | 1,5−ジアリル−3−トリフルオロメチル−δ2−ピラゾリンのラセミ誘導体及びエナンチオマーとして純粋な誘導体の調製方法 |
PL02367773A PL367773A1 (en) | 2001-06-18 | 2002-06-06 | Method of preparing derivatives of 1.5-diaryl-3-trifluoromethyl-delta2-pyrazolines that are racemic and enantiomerically pure |
BR0211009-1A BR0211009A (pt) | 2001-06-18 | 2002-06-06 | Processo para a preparação de derivados racêmicos e enantiomericamente puros de 1,5-diaril-3-trifluormetil-delta2 pirazolinas |
MXPA03011783A MXPA03011783A (es) | 2001-06-18 | 2002-06-06 | Procedimiento para la preparacion de derivados de 1,5-diaril-3-trifluorometil-?¦-pirazolinas racemicas y enantiomericamente puras. |
SI200230277T SI1408035T1 (sl) | 2001-06-18 | 2002-06-06 | Postopek za pripravo derivatov 1,5-diaril-3-trifluometil-delta-2-pirazolinov grozdne kisline in enentiomericno cisti |
EP02735442A EP1408035B1 (en) | 2001-06-18 | 2002-06-06 | Method of preparing derivatives of 1.5-diaryl-3-trifluoromethyl-delta2-pyrazolines that are racemic and enantiomerically pure |
SK42-2004A SK422004A3 (en) | 2001-06-18 | 2002-06-06 | Method of preparing derivatives of 1,5-diaryl-3-trifluoromethyl- delta2-pyrazolines that are racemic and enantiomerically pure |
KR10-2003-7016500A KR20040018275A (ko) | 2001-06-18 | 2002-06-06 | 1,5-디아릴-3-트리플루오르메틸-δ²-피라졸린의 라셈체와거울상이성질에서 순수한 유도체의 제조 공정 |
HU0401715A HUP0401715A3 (en) | 2001-06-18 | 2002-06-06 | Method of preparing derivatives of 1,5-diaryl-3-trifluoromethyl-delta2-pyrazolines that are racemic and enantiomerically pure |
CA2451132A CA2451132C (en) | 2001-06-18 | 2002-06-06 | Process for the preparation of racemic and enantiomerically pure derivatives of 1,5-diaryl-3-trifluoromethyl-.delta.2-pyrazolines |
NO20035642A NO20035642L (no) | 2001-06-18 | 2003-12-17 | Fremgangsmate for fremstilling av derivater av 1,5-diaryl-3-trifluormetyl-delta2-pyrazoliner som er racemisk og enantiomerisk rene |
BG108524A BG108524A (bg) | 2001-06-18 | 2004-01-13 | М...'од за пол"-аван... на ра-...ми-ни и ...нан'иом...рно -и''и производни на 1,5-диарил-3-'ри"л"ором...'ил-д...л'а2 пиразолини |
ZA2004/00343A ZA200400343B (en) | 2001-06-18 | 2004-01-16 | Method of preparing derivatives of 1,5-diaryl-3-trifluoromethyl-del ta2-pyrazolines that are racemic and enantiomerically pure |
US11/007,449 US6958403B2 (en) | 2001-06-18 | 2004-12-08 | Procedure for the preparation of racemic and enantiomerically pure derivatives of 1,5 diaryl-3-trifluorromethyl-Δ2-pyrazolines |
US11/006,931 US20050096474A1 (en) | 2001-06-18 | 2004-12-08 | Procedure for the preparation of racemic derivatives of 1,5-diaryl-3-trifluoromethyl-delta2-pyrazolines |
HK05109018A HK1077058A1 (en) | 2001-06-18 | 2005-10-13 | Method of preparing derivatives of 1,5-diaryl-3-trifluoromethyl-delta2-pyrazolnes that are racemic and enantiomerically pure |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ES200101412A ES2183720B1 (es) | 2001-06-18 | 2001-06-18 | Procedimiento para la preparacion de derivados de 1,5-diaril-3-trifluorometil-delta2-pirazolinas racemicas y enantiomericamente puras. |
ESP200101412 | 2001-06-18 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/312,194 A-371-Of-International US6846935B2 (en) | 2001-06-18 | 2002-06-06 | Procedure for the preparation of racemic and enantionmerically pure derivatives of 1,5-diaryl-3-trifluoromethyl-Δ2-pyrazolines |
US11/006,931 Division US20050096474A1 (en) | 2001-06-18 | 2004-12-08 | Procedure for the preparation of racemic derivatives of 1,5-diaryl-3-trifluoromethyl-delta2-pyrazolines |
US11/007,449 Division US6958403B2 (en) | 2001-06-18 | 2004-12-08 | Procedure for the preparation of racemic and enantiomerically pure derivatives of 1,5 diaryl-3-trifluorromethyl-Δ2-pyrazolines |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2002102781A1 true WO2002102781A1 (es) | 2002-12-27 |
Family
ID=8498105
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/ES2002/000274 WO2002102781A1 (es) | 2001-06-18 | 2002-06-06 | Procedimiento para la preparación de derivados de 1,5-diaril-3-trifluorometil-delta2-pirazolinas racémicas y enantioméricamente puras |
Country Status (27)
Country | Link |
---|---|
US (3) | US6846935B2 (es) |
EP (1) | EP1408035B1 (es) |
JP (1) | JP2005502604A (es) |
KR (1) | KR20040018275A (es) |
CN (1) | CN1275946C (es) |
AR (1) | AR036050A1 (es) |
AT (1) | ATE315030T1 (es) |
BG (1) | BG108524A (es) |
BR (1) | BR0211009A (es) |
CA (1) | CA2451132C (es) |
CZ (1) | CZ200481A3 (es) |
DE (1) | DE60208551T2 (es) |
DK (1) | DK1408035T3 (es) |
EE (1) | EE200400016A (es) |
ES (2) | ES2183720B1 (es) |
HK (1) | HK1077058A1 (es) |
HU (1) | HUP0401715A3 (es) |
IL (1) | IL159367A0 (es) |
MX (1) | MXPA03011783A (es) |
NO (1) | NO20035642L (es) |
PL (1) | PL367773A1 (es) |
PT (1) | PT1408035E (es) |
RU (1) | RU2288915C2 (es) |
SI (1) | SI1408035T1 (es) |
SK (1) | SK422004A3 (es) |
WO (1) | WO2002102781A1 (es) |
ZA (1) | ZA200400343B (es) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005120584A2 (en) * | 2004-06-03 | 2005-12-22 | The Trustees Of Columbia University In The City Of New York | Radiolabeled arylsulfonyl compounds and uses thereof |
Families Citing this family (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2183720B1 (es) * | 2001-06-18 | 2004-01-16 | Esteve Labor Dr | Procedimiento para la preparacion de derivados de 1,5-diaril-3-trifluorometil-delta2-pirazolinas racemicas y enantiomericamente puras. |
DE102004057303A1 (de) * | 2004-11-26 | 2006-06-01 | Merck Patent Gmbh | Stabile Kristallmodifikationen von DOTAP Chlorid |
EP1757587A1 (en) * | 2005-07-15 | 2007-02-28 | Laboratorios Del Dr. Esteve, S.A. | Substituted pyrazoline compounds, their preparation and use as medicaments |
US9376420B2 (en) * | 2012-10-25 | 2016-06-28 | Yuhan Corporation | 4,5-dihydro-1H-pyrazole derivative or salts thereof, and pharmaceutical composition comprising same |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999062884A1 (es) * | 1998-05-29 | 1999-12-09 | Laboratorios Del Dr. Esteve, S.A. | Derivados de pirazolinas, su preparacion y su aplicacion como medicamentos |
WO2000076503A1 (en) * | 1999-06-16 | 2000-12-21 | Temple University - Of The Commonwealth System Of Higher Education | 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines as inhibitors of cyclooxygenase-2 |
Family Cites Families (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE788658R (fr) * | 1971-09-09 | 1973-03-12 | Hoechst Ag | Derives de 3-(3', 4'-dichloro-6'-alkylphenyl) -delta2-pyrazolines, leurpreparation et leur utilisation comme agents d'azurage |
ES2183720B1 (es) * | 2001-06-18 | 2004-01-16 | Esteve Labor Dr | Procedimiento para la preparacion de derivados de 1,5-diaril-3-trifluorometil-delta2-pirazolinas racemicas y enantiomericamente puras. |
-
2001
- 2001-06-18 ES ES200101412A patent/ES2183720B1/es not_active Expired - Fee Related
-
2002
- 2002-06-06 HU HU0401715A patent/HUP0401715A3/hu unknown
- 2002-06-06 DE DE60208551T patent/DE60208551T2/de not_active Expired - Lifetime
- 2002-06-06 BR BR0211009-1A patent/BR0211009A/pt not_active IP Right Cessation
- 2002-06-06 EP EP02735442A patent/EP1408035B1/en not_active Expired - Lifetime
- 2002-06-06 MX MXPA03011783A patent/MXPA03011783A/es active IP Right Grant
- 2002-06-06 CZ CZ200481A patent/CZ200481A3/cs unknown
- 2002-06-06 EE EEP200400016A patent/EE200400016A/xx unknown
- 2002-06-06 SI SI200230277T patent/SI1408035T1/sl unknown
- 2002-06-06 JP JP2003505323A patent/JP2005502604A/ja active Pending
- 2002-06-06 RU RU2004101050/04A patent/RU2288915C2/ru not_active IP Right Cessation
- 2002-06-06 CN CNB028143280A patent/CN1275946C/zh not_active Expired - Fee Related
- 2002-06-06 AT AT02735442T patent/ATE315030T1/de active
- 2002-06-06 IL IL15936702A patent/IL159367A0/xx unknown
- 2002-06-06 KR KR10-2003-7016500A patent/KR20040018275A/ko not_active Application Discontinuation
- 2002-06-06 ES ES02735442T patent/ES2256483T3/es not_active Expired - Lifetime
- 2002-06-06 PL PL02367773A patent/PL367773A1/xx not_active Application Discontinuation
- 2002-06-06 WO PCT/ES2002/000274 patent/WO2002102781A1/es active IP Right Grant
- 2002-06-06 US US10/312,194 patent/US6846935B2/en not_active Expired - Fee Related
- 2002-06-06 CA CA2451132A patent/CA2451132C/en not_active Expired - Fee Related
- 2002-06-06 SK SK42-2004A patent/SK422004A3/sk unknown
- 2002-06-06 DK DK02735442T patent/DK1408035T3/da active
- 2002-06-06 PT PT02735442T patent/PT1408035E/pt unknown
- 2002-06-12 AR ARP020102218A patent/AR036050A1/es not_active Application Discontinuation
-
2003
- 2003-12-17 NO NO20035642A patent/NO20035642L/no not_active Application Discontinuation
-
2004
- 2004-01-13 BG BG108524A patent/BG108524A/bg unknown
- 2004-01-16 ZA ZA2004/00343A patent/ZA200400343B/en unknown
- 2004-12-08 US US11/006,931 patent/US20050096474A1/en not_active Abandoned
- 2004-12-08 US US11/007,449 patent/US6958403B2/en not_active Expired - Fee Related
-
2005
- 2005-10-13 HK HK05109018A patent/HK1077058A1/xx not_active IP Right Cessation
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1999062884A1 (es) * | 1998-05-29 | 1999-12-09 | Laboratorios Del Dr. Esteve, S.A. | Derivados de pirazolinas, su preparacion y su aplicacion como medicamentos |
WO2000076503A1 (en) * | 1999-06-16 | 2000-12-21 | Temple University - Of The Commonwealth System Of Higher Education | 1-(4-sulfamylaryl)-3-substituted-5-aryl-2-pyrazolines as inhibitors of cyclooxygenase-2 |
Non-Patent Citations (3)
Title |
---|
CANADIAN JOURNAL OF CHEMISTRY, vol. 57, 1979, pages 360 - 366 * |
DATABASE CA [online] MUKAI ET AL.: "On the syntheses and the optical properties of optically active 2-pyrazoline compounds", XP002963126, accession no. STN Database accession no. 1990:186855 * |
JACQUES J. ET AL.: "Enantiomers, racemates and resolutions", 1991, KRIEGER PUBLISHING COMPANY, FLORIDA, USA, pages: 258 - 261, XP002939164 * |
Cited By (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2005120584A2 (en) * | 2004-06-03 | 2005-12-22 | The Trustees Of Columbia University In The City Of New York | Radiolabeled arylsulfonyl compounds and uses thereof |
WO2005120584A3 (en) * | 2004-06-03 | 2006-06-08 | Univ Columbia | Radiolabeled arylsulfonyl compounds and uses thereof |
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200815358A (en) | Organic compounds | |
JP2006508092A (ja) | γ−セクレターゼの阻害のための環状スルファミド | |
FR2732967A1 (fr) | 1-phenylpyrazole-3-carboxamides substitues, actifs sur la neurotensine, leur preparation, les compositions pharmaceutiques en contenant | |
CN101218207A (zh) | 组织蛋白酶半胱氨酸蛋白酶抑制剂 | |
ES2837361T3 (es) | Proceso para preparar compuestos de indol-carboxamida | |
ES2256483T3 (es) | Procedimiento para la obtencion de derivados de 1,5-diaril-3-trifluorometil-delta2-pirazolinas racemicas y enantiomericamente puras. | |
ES2228109T3 (es) | Nuevos imidazoles con actividad antiinflamatoria. | |
GB2348202A (en) | Novel salts of (1S,4R)-cis-4-[2-amino-6-(cyclopropylamino-9H-purin-9-yl]- 2-cyclopentene-1-methanol | |
US20050069276A1 (en) | Deuterated pyrazolopyrimidinones and drugs containing said compounds | |
ES2349918T3 (es) | Derivados intermedios de halofenilo y su empleo en un procedimiento para la preparación de derivados azólicos. | |
ES2257929B1 (es) | Derivados de pirazolina, procedimiento para su obtencion y utilizacion de los mismos como agentes terapeuticos. | |
JP2007522152A (ja) | メチル−α−5−[4,5,6,7−テトラヒドロ[3,2−C]チエノピリジル]−(2−クロロフェニル)アセテートのラセミ化合物の分割 | |
JP3496078B2 (ja) | 新規なヒドラゾン誘導体及びその製造法 | |
HUT72073A (en) | Process for preparing enantiomerically pure 6-[(4-chlorophenyl)(1h-1,2,4-triazol-1-yl)methyl]-1-methyl-1h-benzotriazole | |
US20220024910A1 (en) | Process for Making Biologically Active Compounds and Intermediates Thereof | |
KR100958678B1 (ko) | 시스-디메크로틴산 및 이의 염의 제조방법 | |
JP3613657B2 (ja) | 光学活性N置換α−アミノ−γ−ハロゲノ酪酸エステルの製造方法 | |
JPH072802A (ja) | 光学活性トリアゾール誘導体の製造法 | |
EP4298100A1 (en) | Process for obtaining avapritinib and its intermediates | |
HU219351B (en) | Process for producing n-sulfonilamino phenyl ketone derivatives | |
JP2001139563A (ja) | 1,2,3−ベンゾトリアジン−4(3h)オン誘導体の製造方法 | |
TW201125852A (en) | Synthesis of substituted pyrazoline carboxamidine derivatives |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WWE | Wipo information: entry into national phase |
Ref document number: 10312194 Country of ref document: US |
|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 159367 Country of ref document: IL |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2451132 Country of ref document: CA Ref document number: PA/a/2003/011783 Country of ref document: MX Ref document number: 1020037016500 Country of ref document: KR |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2003505323 Country of ref document: JP |
|
ENP | Entry into the national phase |
Ref document number: 10852402 Country of ref document: BG Kind code of ref document: A |
|
WWE | Wipo information: entry into national phase |
Ref document number: 108524 Country of ref document: BG |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002735442 Country of ref document: EP Ref document number: PV2004-81 Country of ref document: CZ Ref document number: 2004/00343 Country of ref document: ZA Ref document number: 422004 Country of ref document: SK Ref document number: 200400343 Country of ref document: ZA Ref document number: 20028143280 Country of ref document: CN |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2002310782 Country of ref document: AU Ref document number: 59/KOLNP/2004 Country of ref document: IN |
|
WWP | Wipo information: published in national office |
Ref document number: 2002735442 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWP | Wipo information: published in national office |
Ref document number: PV2004-81 Country of ref document: CZ |
|
WWG | Wipo information: grant in national office |
Ref document number: 2002735442 Country of ref document: EP |